Health Care: Drugs

Geron Corp (GERN: NASDAQ)

$2.2 n/a | n/a%
09/29/16 - 04:00 PM ET
Company Profile
Price and Volume
Recent Price 2.20
52 Week High 5.30
52 Week Low 1.84
Avg. Daily Vol. (Mil) 1.79
Beta (3 year) 3.76
Share Related Items
Mkt Cap (Mil) 350.11
Shares Out (Mil) 159.14
Float (Mil) 134.42
Dividend Information
Yield % 0.00
Annual Dividend 0.00
Payout Ratio 0.00
Financial Strength
Quick Ratio 15.60
Current Ratio 15.70
LT Debt/ Equity 0.00
Total Debt / Equity 0.00
Valuation Ratios
Price Earnings 213.90
Price/Sales 9.58
Price/Book 2.69
Price/Cash Flow 128.00
Per Share Data
Earnings 0.01
Sales 0.23
Book Value 0.82
Cash Flow 0.02
Business Summary
Geron Corp is a biopharmaceutical company that supports the clinical stage development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies, by Janssen Biotech, Inc., or Janssen.
General Information
149 Commonwealth Drive
Suite 2070
Menlo Park, CA 94025
Industry : Drugs
Sector: Health Care
Employees: 17
CEO: Dr. John A. Scarlett,M.D
Short Interest
Current Month (Mil) 26.98
Previous Month (Mil) 26.79
Short Interest Ratio (Days) 11.70
Management Effectiveness
Return on Equity 1.00
Return on Assets 0.90
Return on Investments 1.00
Gross Margin n.a.
EBIT Margin -0.50
Profit Margin 3.40

Portfolios with GERN

Latest GERN Headlines from TheStreet

More Financial News for GERN

Press Releases for GERN

See All Press Releases
brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter